AGER and Alzheimer disease: This interaction not only exacerbates amyloid pathology in AD but also contributes to chronic inflammation and BBB dysfunction, highlighting the potential therapeutic value of targeting the S100B/RAGE axis in neurodegenerative disorders [109,110].